Literature DB >> 12634455

A glucocorticoid reduces adverse effects of adenovirus vectors in the cochlea.

Shin-ichi Ishimoto1, Kohei Kawamoto, Timo Stöver, Sho Kanzaki, Tatsuya Yamasoba, Yehoash Raphael.   

Abstract

Gene transfer using a recombinant adenovirus is a powerful tool for research and clinical applications, but its cytotoxicity and immune response limit its use, especially when repeated application of the vector is necessary. This study investigated the effects of dexamethasone (DEX)-induced immunosuppression on the outcome of adenovirus gene transfer in guinea pig inner ears. Animals received DEX for 29 days. Their inner ear was inoculated with 5 micro l of adenovirus vector twice, on days 5 and 26. Auditory brainstem response was measured on days 1, 8 and 29. The animals were sacrificed on day 29, and reporter gene expression was evaluated. In control animals that received no DEX, postinoculation threshold shifts and lesions in the organ of Corti were observed and reporter gene expression was absent. In contrast, DEX-treated ears were largely protected, and transduction of inner ear cells was readily apparent. These data demonstrate that immunosuppressive treatment can reduce the negative consequences of repeated adenovirus-mediated gene therapy. Copyright 2003 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12634455     DOI: 10.1159/000069000

Source DB:  PubMed          Journal:  Audiol Neurootol        ISSN: 1420-3030            Impact factor:   1.854


  6 in total

Review 1.  Development of gene therapy for inner ear disease: Using bilateral vestibular hypofunction as a vehicle for translational research.

Authors:  Hinrich Staecker; Mark Praetorius; Douglas E Brough
Journal:  Hear Res       Date:  2011-01-18       Impact factor: 3.208

2.  Transient pretreatment with glucocorticoid ablates innate toxicity of systemically delivered adenoviral vectors without reducing efficacy.

Authors:  Sergey S Seregin; Daniel M Appledorn; Aaron J McBride; Nathaniel J Schuldt; Yasser A Aldhamen; Tyler Voss; Junping Wei; Matthew Bujold; William Nance; Sarah Godbehere; Andrea Amalfitano
Journal:  Mol Ther       Date:  2009-01-27       Impact factor: 11.454

3.  Over-expression of BDNF by adenovirus with concurrent electrical stimulation improves cochlear implant thresholds and survival of auditory neurons.

Authors:  Jennifer A Chikar; Deborah J Colesa; Donald L Swiderski; Adriana Di Polo; Yehoash Raphael; Bryan E Pfingst
Journal:  Hear Res       Date:  2008-08-19       Impact factor: 3.208

Review 4.  Strategies to overcome host immunity to adenovirus vectors in vaccine development.

Authors:  Erin E Thacker; Laura Timares; Qiana L Matthews
Journal:  Expert Rev Vaccines       Date:  2009-06       Impact factor: 5.217

5.  Viral vector tropism for supporting cells in the developing murine cochlea.

Authors:  Abraham M Sheffield; Samuel P Gubbels; Michael S Hildebrand; Stephen S Newton; John A Chiorini; Giovanni Di Pasquale; Richard J H Smith
Journal:  Hear Res       Date:  2011-04-22       Impact factor: 3.208

6.  Cochlear implants and ex vivo BDNF gene therapy protect spiral ganglion neurons.

Authors:  Darius Rejali; Valerie A Lee; Karen A Abrashkin; Nousheen Humayun; Donald L Swiderski; Yehoash Raphael
Journal:  Hear Res       Date:  2007-03-07       Impact factor: 3.208

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.